What it is
ACE-031, also called ramatercept, is a lab-made fusion protein that works as a decoy for the signals that stop muscle from growing. It joins the outer, signal-catching part of the activin receptor type IIB (ActRIIB) to the Fc tail of a human antibody (IgG1). In the bloodstream it binds myostatin "and other negative regulators of muscle mass" before they reach muscle (Attie et al. 2013, PMID 23169607; Campbell et al. 2017, PMID 27462804).
It was developed for Duchenne muscular dystrophy, a genetic disease in which muscle wastes from childhood.
| Property | Value | Source |
|---|---|---|
| Type | ActRIIB extracellular domain fused to human IgG1 Fc | Campbell 2017 |
| Target | Myostatin and related ligands | Attie 2013; Campbell 2017 |
| Route in trials | Injection under the skin | Attie 2013; Campbell 2017 |
| Half-life | 10–15 days | Attie 2013 |
| Registered studies | 4 (2 completed, 2 terminated) | ClinicalTrials.gov, 2026-11-16 |
It is not a short peptide. Libraries and vendor shops file ACE-031 with peptides, but a receptor domain fused to an antibody tail is a large protein. The library keeps an entry because readers arrive with the name; the first fact a reader should have is what kind of molecule it is.
What the trials showed
Healthy volunteers. In a double-blind study, 48 healthy post-menopausal women were randomised 3 to 1 to a single injection of ACE-031 (0.02–3 mg/kg) or placebo. At day 29, the 3 mg/kg group showed a 3.3% rise in total lean mass measured by DXA scan and a 5.1% rise in thigh muscle volume measured by MRI, both statistically significant. Blood markers suggested effects on bone and fat as well. The main side effect named in the abstract was redness at the injection site (Attie et al. 2013).
Boys with Duchenne. The next trial gave ACE-031 under the skin every two to four weeks to boys who could still walk, against placebo, at rising dose levels. Its main aim was safety. It was stopped after the second dose level because of nosebleeds (epistaxis) and telangiectasias — small, dilated blood vessels. The effects on muscle were trends: walking distance in the six-minute walk test held up better than on placebo, lean mass and bone density rose and fat fell, but none of this reached statistical significance. The authors wrote that "non-muscle-related adverse events contributed to the decision to discontinue the study" (Campbell et al. 2017).
| Study (ClinicalTrials.gov) | People enrolled | Status |
|---|---|---|
| NCT00755638 — single dose, healthy post-menopausal women | 48 | Completed |
| NCT00952887 — healthy post-menopausal women | 70 | Completed |
| NCT01099761 — Duchenne | 24 | Terminated, "based on preliminary safety data" |
| NCT01239758 — Duchenne extension | 11 | Terminated, "based on preliminary safety data" |
Why the side effects matter for the whole idea. Both trial reports describe ACE-031 as binding myostatin "and related ligands" — other members of the same growth-factor family — and the Duchenne authors called the side effects that stopped the trial non-muscle-related. The library's myostatin inhibitor peptides entry follows that lesson through the rest of the class, and follistatin covers the body's own protein that blocks the same signals.
What is not established: any benefit in people with a muscle disease, any long-term safety record, and anything at all in healthy young adults or athletes — no such study is registered.
Where it stands
ACE-031 has never been approved, and its registered development ended with the two terminated Duchenne studies. It is still sold online as a research chemical labelled a "peptide", which the trial record does not support. MuscleLedger's ACE-031 page covers how it is discussed in gyms. The decision whether a muscle-wasting condition warrants any experimental treatment belongs to a neuromuscular specialist.
Sources opened 2026-11-16: Attie et al., Muscle & Nerve 2013 (PMID 23169607); Campbell et al., Muscle & Nerve 2017 (PMID 27462804); ClinicalTrials.gov API v2 records NCT00755638, NCT00952887, NCT01099761, NCT01239758; PubMed E-utilities counts.
